ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, lncRNA-BGL3 expression decreased the survival of Bcr–Abl-positive K562 leukemic cells and stimulated the apoptosis induced by imatinib, a tyrosine kinase inhibitor used in the treatment of Bcr–Abl CML.